Seeking Alpha

Goldman says the court ruling against Par Pharmaceutical (PRX -1.3%) regarding patents covering...

Goldman says the court ruling against Par Pharmaceutical (PRX -1.3%) regarding patents covering Lovaza eliminates a key upside opportunity, adding that the extent of the impact on growth is unclear at this point. The firm maintains its Neutral rating on the shares.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector